On December 31, 2026, the Drug Enforcement Administration’s (DEA) telemedicine flexibilities for controlled substances are set to expire. The DEA has extended them four times since the COVID-19 public health emergency. Another extension is possible but not guaranteed, so prescribers should be ready either way.
The DEA’s January 2025 proposal would create a special registration pathway for eligible practitioners who prescribe controlled substances via telemedicine without first evaluating the patient in person. It would also cover certain direct-to-consumer telemedicine platforms.
What the Proposed Telehealth Rule Would Require
The White House Office of Information and Regulatory Affairs received the DEA’s draft final rule on August 25, 2026. As of November 19, it was still under review. The DEA’s regulatory agenda lists November as its target for final action.
The final version could differ, but here’s what the proposal includes:
- A special registration. Eligible practitioners using this pathway would generally need a DEA-issued State Telemedicine Registration for each state where they prescribe controlled substances to patients via telemedicine. Certain direct-to-consumer platforms would also need to register. Schedule II prescribing would require an advanced registration and would be limited to specified specialties or practice settings. The DEA also proposed a same-state restriction and a monthly limit on Schedule II prescribing under the pathway.
- Interim PDMP checks. Before issuing a Schedule II–V prescription under the special registration, the practitioner would check the prescription drug monitoring program (PDMP) in the jurisdictions where the patient and prescriber are located, as well as in jurisdictions that have PDMP reciprocity agreements with either one. The proposal calls for a one-year lookback, or all available data if less than a year is available.
- A nationwide check, later. The proposal would expand the check to all 50 states and any U.S. district or territory that maintains a PDMP, starting three years after the final rule takes effect. If a nationwide check is unavailable at the three-year mark, the interim checks would continue, and Schedule II prescriptions under the special registration would be limited to patients in the prescriber’s state.
One Rule, Several Possible Workflows
Registration is the paperwork you complete and renew. The PDMP check is a recurring task. As proposed, the prescriber would check before issuing each special registration prescription, including for patients in the same state.
What’s less certain is how far that check would reach. The final rule could land anywhere along this range, and each step means a different workflow:
- The patient’s state, the prescriber’s state and both states’ reciprocity partners. This is the interim check as proposed. A prescriber in one state treating a patient in another would run at least two checks. Depending on the states and the prescriber’s permissions, a single search may return data from multiple jurisdictions.
- Every state and territory. The proposal includes a nationwide check as a later phase, delayed by three years. It is the widest version and the least certain, since the DEA would first need to decide that a nationwide check is possible.
While not included in the rule itself, additional considerations are possible if the DEA changes its approach.
- The patient’s state only. This is the narrowest version. Prescribers would query a PDMP for each patient, but they would still need access in every state where their patients live.
- The patient’s state plus its reciprocity partners. Many states share PDMP data with each other. One check could return data from several states, depending on which agreements the patient’s state has in place.
Each version changes which jurisdictions the workflow must cover and what a compliance team must document. State PDMP requirements would continue to apply in addition to any federal rule.
The date may slip again. But some version of a federal PDMP check for telehealth prescribing is coming, and implementing the workflow will take time.
How to Prepare for the DEA Telemedicine Rule, Whatever Version Lands
Whatever shape the final rule takes, the work grows as you add states. Our free 30-minute readiness assessment maps your current footprint against each version of the rule, with no obligation. We work with state PDMPs every day and have already built a multi-state check that runs inside the clinical workflow.
With Bamboo’s large national footprint and support for PMP InterConnect®, which connects 51 PDMPs, a national search of PDMPs could be within reach using existing technology. However, differences in technology and policy across states could pose significant challenges to realizing this goal.
Frequently Asked Questions: The DEA Telemedicine Rule
When do the DEA telemedicine flexibilities expire?
The DEA’s telemedicine flexibilities for controlled substances are set to expire on December 31, 2026. The DEA has extended them four times since the COVID-19 public health emergency. Another extension is possible, but it isn’t guaranteed.
Do telehealth providers still need to see a patient in person before prescribing a controlled substance?
Telehealth providers do not always need to see a patient in person before prescribing a controlled substance. Federal telemedicine flexibilities currently let authorized providers prescribe certain controlled substances without a prior in-person exam. Those flexibilities are set to run through the end of 2026. But this is a temporary policy that has already been extended multiple times. Either way, state PDMP requirements still apply regardless of which prescribing pathway a provider uses.
Is the DEA’s telemedicine special registration rule final?
The DEA’s telemedicine special registration rule is not final yet. The DEA sent it to the White House Office of Management and Budget for review on August 25, 2026. Until the final rule is published, its requirements are proposed and may change.
What PDMP checks would the proposed rule require?
As proposed, a practitioner would check the PDMP in the patient’s state and in the practitioner’s own state before issuing a Schedule II–V prescription through telemedicine. The check would also cover any states that share data with either one through reciprocity agreements. The proposal would later expand the check nationwide, after a three-year delay. The final rule could narrow or change that scope.
Would state PDMP requirements still apply under a federal rule?
State PDMP requirements would still apply under a federal rule. As proposed, the federal rule would set a minimum. Each state would keep its own PDMP rules, and a telehealth visit could fall under more than one state’s rules at once.
Should we wait for the final rule before changing our workflow?
Waiting for the final rule leaves little time to prepare. The flexibilities are set to expire on December 31, 2026, and setting up PDMP access and workflows across states takes time. Planning now for the full range of possible outcomes means fewer surprises when the rule lands.
Is your PDMP workflow ready? Connect with us at bamboohealth.com/contact to schedule your free readiness assessment.